Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer: A Phase 1b Clinical Trial

IMPORTANCE: The phosphatidylinositol 3-kinase (PI3K) pathway is frequently activated in patients with estrogen receptor–positive (ER+), endocrine therapy–resistant breast cancers. OBJECTIVE: To assess the maximum tolerated dose (MTD), safety, and activity of alpelisib, an oral, PI3Kα-specific inhibi...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:JAMA Oncol
Asıl Yazarlar: Juric, Dejan, Janku, Filip, Rodón, Jordi, Burris, Howard A., Mayer, Ingrid A., Schuler, Martin, Seggewiss-Bernhardt, Ruth, Gil-Martin, Marta, Middleton, Mark R., Baselga, José, Bootle, Douglas, Demanse, David, Blumenstein, Lars, Schumacher, Karl, Huang, Alan, Quadt, Cornelia, Rugo, Hope S.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Medical Association 2018
Konular:
Original Investigation
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6439561/
https://ncbi.nlm.nih.gov/pubmed/30543347
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.4475
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller